Pain biotech Flexion Therapeutics files for a $86 million IPO
Flexion Therapeutics, which is developing injectable pain therapies for osteoarthritis, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Burlington, MA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol FLXN. BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.